Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Glial Cells and Their Contribution to the Mechanisms of Action of Cannabidiol in Neuropsychiatric Disorders

Full text
Author(s):
Scarante, Franciele F. [1] ; Ribeiro, Melissa A. [1] ; Almeida-Santos, Ana F. [2] ; Guimaraes, Francisco S. [1] ; Campos, Alline C. [1]
Total Authors: 5
Affiliation:
[1] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pharmacol, Ribeirao Preto - Brazil
[2] Univ Fed Minas Gerais, Biol Sci Inst, Dept Physiol & Biophys, Belo Horizonte, MG - Brazil
Total Affiliations: 2
Document type: Review article
Source: FRONTIERS IN PHARMACOLOGY; v. 11, FEB 4 2021.
Web of Science Citations: 0
Abstract

Cannabidiol (CBD) is a phytocannabinoid with a broad-range of therapeutic potential in several conditions, including neurological (epilepsy, neurodegenerative diseases, traumatic and ischemic brain injuries) and psychiatric disorders (schizophrenia, addiction, major depressive disorder, and anxiety). The pharmacological mechanisms responsible for these effects are still unclear, and more than 60 potential molecular targets have been described. Regarding neuropsychiatric disorders, most studies investigating these mechanisms have focused on neuronal cells. However, glial cells (astrocytes, oligodendrocytes, microglia) also play a crucial role in keeping the homeostasis of the central nervous system. Changes in glial functions have been associated with neuropathological conditions, including those for which CBD is proposed to be useful. Mostly in vitro studies have indicated that CBD modulate the activation of proinflammatory pathways, energy metabolism, calcium homeostasis, and the proliferative rate of glial cells. Likewise, some of the molecular targets proposed for CBD actions are f expressed in glial cells, including pharmacological receptors such as CB1, CB2, PPAR-gamma, and 5-HT1A. In the present review, we discuss the currently available evidence suggesting that part of the CBD effects are mediated by interference with glial cell function. We also propose additional studies that need to be performed to unveil the contribution of glial cells to CBD effects in neuropsychiatric disorders. (AU)

FAPESP's process: 19/25984-0 - Design and characterization of a new approach for cannabidiol (CBD) delivery into the central nervous system: in vivo imaging of CBD nanoprobes
Grantee:Alline Cristina de Campos
Support type: Regular Research Grants
FAPESP's process: 19/09178-3 - Involvement of endocannabinoid signaling and neuroplasticity within the prefrontal cortex in the behavioral effects of the combination cannabidiol and escitalpram in stressed mice
Grantee:Franciele Franco Scarante
Support type: Scholarships in Brazil - Doctorate
FAPESP's process: 17/24304-0 - New perspectives in the use of drugs that modify atypical neurotransmitters in the treatment of neuropsychiatric disorders
Grantee:Francisco Silveira Guimaraes
Support type: Research Projects - Thematic Grants